iCAD, Inc. Stock

Equities

ICAD

US44934S2068

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:00:00 2024-05-16 pm EDT 5-day change 1st Jan Change
1.77 USD +8.59% Intraday chart for iCAD, Inc. +21.23% 0.00%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 18.79M Sales 2025 * 23.63M Capitalization 46.67M
Net income 2024 * -6M Net income 2025 * -4M EV / Sales 2024 * 2.48 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.97 x
P/E ratio 2024 *
-7.59 x
P/E ratio 2025 *
-9.83 x
Employees 68
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.67%
More Fundamentals * Assessed data
Dynamic Chart
1 day+8.59%
1 week+22.92%
Current month+23.78%
1 month+8.59%
3 months+23.78%
6 months+36.15%
More quotes
1 week
1.45
Extreme 1.45
1.88
1 month
1.40
Extreme 1.4
1.88
Current year
1.25
Extreme 1.25
2.65
1 year
1.06
Extreme 1.06
3.97
3 years
1.05
Extreme 1.05
19.00
5 years
1.05
Extreme 1.05
21.44
10 years
1.05
Extreme 1.05
21.44
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 22-01-09
Director of Finance/CFO 49 21-01-31
Chief Operating Officer - 23-04-30
Members of the board TitleAgeSince
Chief Executive Officer 59 22-01-09
Director/Board Member 59 15-12-08
Director/Board Member 60 18-09-25
More insiders
Date Price Change Volume
24-05-16 1.77 +8.59% 297,963
24-05-15 1.63 +3.16% 406,444
24-05-14 1.58 +1.28% 128,493
24-05-13 1.56 +3.31% 96,708
24-05-10 1.51 +3.42% 78,054

Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT

More quotes
iCAD, Inc. provides artificial intelligence-powered cancer detection. Its ProFound Breast Health Suite enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Cancer Detection segment solutions include advanced artificial intelligence and image analysis workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging and computed tomography. ProFound Suite offers 360-degree solutions for cancer detection, density assessment, and personalized risk evaluation, all based on a 2D or 3D mammogram’s collection of images. ProFound Density Assessment standardizes and simplifies breast density reporting, algorithmically examining a woman’s breast anatomy from the mammogram image.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.77 USD
Average target price
4.833 USD
Spread / Average Target
+173.07%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW